Business
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect
About this update from Bioatla, Inc.
[{"type":"text","content":"Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part 2 non-small cell lung cancer (NSCLC) study in 1H23; FDA feedback and initiation of Phase 2, part 2 remain on track for 2H23 Enrolling BA3021 Phase 2 NSCLC study including more frequent, dose-intensive regimen; anticipated interim readout remains on track for 2H23 Enrolling CAB-ROR2 BA3021 Phase 2 squamous cell carcinoma of the head & neck (SCCHN) study as anticipatedPhase 1 dose-escalation CAB-CTLA-4 (BA3071) study ongoing including with PD-1 combination; anticipated data readout and initiation of Phase 2 remain on track for 2H23 FPI anticipated for CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 study in 1H23Cash balance of $192.7 million expected to provide funding into 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2023, and provided highlights on its clinical programs. “BioAtla continues to progress our robust CAB pipeline, including our Phase 2, part 2 potentially registrational BA3011 UPS study and successful identification of ROR2-positive tumors using our validated CTC assay in metastatic melanoma patients,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “BioAtla has several important milestones and value inflection points that remain on track for this year, including initiation of our Phase 2, part 2 potentially registrational BA3011 trial in NSCLC following anticipated FDA feedback, Phase 2 interim readout for BA3021 in NSCLC, Phase 1 data readout for our CAB-CTLA-4 basket trial and initiation of our Phase 2 BA3071 trial in multiple indications. In addition, we are opening centers for our first CAB bispecific antibody, BA3182 for the potential treatment of adenocarcinomas, ...